Business Description
Nabriva Therapeutics PLC
NAICS : 325414
SIC : 2836
ISIN : IE000OZRGNV6
Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Financial Strength
Name | Current | Vs Industry | Vs History |
---|
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 28.23 | |||||
14-Day RSI | 28.95 | |||||
12-1 Month Momentum % | -99.99 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -44.32 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-Forward-Revenue | 0.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NBRVF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nabriva Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 29.387 | ||
EPS (TTM) ($) | -18.43 | ||
Beta | -3.61 | ||
Volatility % | 173.89 | ||
14-Day RSI | 28.95 | ||
14-Day ATR ($) | 0.000024 | ||
20-Day SMA ($) | 0.0001 | ||
12-1 Month Momentum % | -99.99 | ||
52-Week Range ($) | 0.0001 - 1.9 | ||
Shares Outstanding (Mil) | 3.23 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nabriva Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nabriva Therapeutics PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nabriva Therapeutics PLC Frequently Asked Questions
What is Nabriva Therapeutics PLC(NBRVF)'s stock price today?
The current price of NBRVF is $0.00. The 52 week high of NBRVF is $1.90 and 52 week low is $0.00.
When is next earnings date of Nabriva Therapeutics PLC(NBRVF)?
The next earnings date of Nabriva Therapeutics PLC(NBRVF) is 2024-07-05 Est..
Does Nabriva Therapeutics PLC(NBRVF) pay dividends? If so, how much?
Nabriva Therapeutics PLC(NBRVF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |